[Li+].[CH2:2]([O:9][C:10]1[CH:15]=[CH:14][C:13]([N:16]2[CH2:21][CH2:20][N:19]([CH2:22][CH2:23][C:24]([O-:26])=O)[CH2:18][CH2:17]2)=[CH:12][CH:11]=1)[C:3]1[CH:8]=[CH:7][CH:6]=[CH:5][CH:4]=1.C(N(C(C)C)CC)(C)C.F[P-](F)(F)(F)(F)F.CN(C)C(ON1C2C=CC=CC=2N=N1)=[N+](C)C.Cl.[N+:61]([C:64]1[CH:76]=[CH:75][C:67]([O:68][CH:69]2[CH2:74][CH2:73][NH:72][CH2:71][CH2:70]2)=[CH:66][C:65]=1[C:77]([F:80])([F:79])[F:78])([O-:63])=[O:62]>CN(C)C=O.ClCCl.O1CCCC1>[CH2:2]([O:9][C:10]1[CH:11]=[CH:12][C:13]([N:16]2[CH2:21][CH2:20][N:19]([CH2:22][CH2:23][C:24]([N:72]3[CH2:73][CH2:74][CH:69]([O:68][C:67]4[CH:75]=[CH:76][C:64]([N+:61]([O-:63])=[O:62])=[C:65]([C:77]([F:78])([F:79])[F:80])[CH:66]=4)[CH2:70][CH2:71]3)=[O:26])[CH2:18][CH2:17]2)=[CH:14][CH:15]=1)[C:3]1[CH:4]=[CH:5][CH:6]=[CH:7][CH:8]=13-[4-(4-Benzyloxy-phenyl)-piperazin-1-yl]-propionic acid lithium salt (34 mg; 0.10 mmol, prepared in accordance with Example 22), diisopropylethyl amine (35 μL; 0.20 mmol) and tetramethyl-O-(1H-benzotriazol-1-yl)uronium hexafluorophosphate (38 mg; 0.10 mmol) are diluted in a 2 to 1 mixture of dimethylformamide and tetrahydrofuran (1.5 mL) and the resulting solution is stirred for 5 minutes. A solution of 4-(4-nitro-3-trifluoromethyl-phenoxy)-piperidine hydrochloride (33 mg; 0.10 mmol, prepared in accordance with Example 44) in dimethylformamide (0.5 mL) is added and the reaction is then stirred for 2 hours at room temperature. Following dilution with dichloromethane (10 mL), the organic layer is sequentially washed with water (5 mL), aq. sat. sodium hydrogen carbonate (5 mL), is dried over magnesium sulfate and concentrated under reduced pressure. The residue obtained is finally purified by preparative HPLC to deliver the desired product in pure form (19 mg; 0.03 mmol). The structure was confirmed using Protocol I-B. Calculated mass=613; observed mass=613; HPLC retention time=4.74 min.
読み込み中…